Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

NCT01878890 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT01878890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01878890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Lead sponsor
Institut Bergonié
Phase
Phase 1
Overall status
Completed
Start date
September 5, 2011
Completion date
December 31, 2016
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma, solid tumors